Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 81,834,536
  • Shares Outstanding, K 335,580
  • Annual Sales, $ 14,571 M
  • Annual Income, $ 14,973 M
  • 36-Month Beta 1.12
  • Price/Sales 5.60
  • Price/Cash Flow 7.47
  • Price/Book 1.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
233.00 +4.66%
on 04/18/17
244.15 -0.12%
on 04/28/17
+3.33 (+1.38%)
since 03/28/17
3-Month
209.31 +16.51%
on 01/31/17
250.94 -2.82%
on 02/15/17
+30.66 (+14.38%)
since 01/27/17
52-Week
184.50 +32.17%
on 11/23/16
261.27 -6.66%
on 07/27/16
+25.01 (+11.43%)
since 04/28/16

Most Recent Stories

More News
Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition

Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced it has successfully completed the acquisition of ZELTIQ® Aesthetics, Inc., a medical technology company behind a proprietary...

AGN : 243.86 (+0.33%)
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales

Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.

AGN : 243.86 (+0.33%)
NVS : 77.03 (-0.04%)
RHHBY : 32.6980 (-0.13%)
AMGN : 163.32 (+0.37%)
Juvéderm Vollure(TM) XC Dermal Filler -- Long Lasting FDA-Approved Treatment for Diminishing Nasolabial Folds Now Available at Contour Dermatology & Cosmetic Surgery Center

Contour Dermatology & Cosmetic Surgery Center is the first medical office in the Coachella Valley to offer Juvéderm Vollure(TM) XC - the latest dermal filler from Allergan which is an FDA-approved hyaluronic...

AGN : 243.86 (+0.33%)
Global Tamoxifen Market to Reach $683.6 Million by 2022: Key Vendors are AstraZaneca, Teva Pharmaceutical Industries, Allergan, Mylan, Apotex & Midatech - Research and Markets

Research and Markets has announced the addition of the "Global Tamoxifen Market - 2014 to 2022" report to their offering.

AGN : 243.86 (+0.33%)
TEVA : 31.58 (-0.47%)
Allergan (AGN) Crosses Pivot Point Support at $236.54

Allergan (NYSE:AGN) has opened bearishly below the pivot of $237.76 today and has reached the first level of support at $236.54. Should the shares continue to fall, the support pivots of $235.13 and $232.50...

AGN : 243.86 (+0.33%)
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

JNJ : 123.47 (-0.22%)
LLY : 82.06 (+0.90%)
AGN : 243.86 (+0.33%)
NVS : 77.03 (-0.04%)
RHHBY : 32.6980 (-0.13%)
SNY : 47.30 (+0.83%)
BMY : 56.05 (+0.68%)
Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston

Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology (AAN) annual meeting taking place April...

AGN : 243.86 (+0.33%)
Allergan (AGN) Collaborates with Novartis to Treat NASH

Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic...

CNAT : 8.36 (-4.68%)
AGN : 243.86 (+0.33%)
NVS : 77.03 (-0.04%)
ICPT : 112.35 (-0.78%)
Allergan Set to Possibly Rebound After Yesterday's Selloff of 1.11%

Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $233.00 to a high of $236.41. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $235.80 on...

AGN : 243.86 (+0.33%)
Did Pharma & Biotech M&As Pick Pace in Q1?

Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.

JNJ : 123.47 (-0.22%)
AGN : 243.86 (+0.33%)
SHPG : 176.96 (-0.49%)
GILD : 68.55 (-0.04%)
TEVA : 31.58 (-0.47%)
PFE : 33.92 (+0.18%)
SNY : 47.30 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Support & Resistance

2nd Resistance Point 246.45
1st Resistance Point 245.15
Last Price 243.86
1st Support Level 241.56
2nd Support Level 239.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.